digoxin and Edema

Topics: Angiotensin-Converting Enzyme Inhibitors; Diagnosis, Differential; Digoxin; Diuretics; Dyspnea; Echocardiography; Edema; Exercise Tolerance; Female; Heart Failure; Humans; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Patient Education as Topic; Referral and Consultation; Terminal Care; Ventricular Dysfunction, Left

In diseases with generalized edema caused by decompensated heart and liver diseases or kidney failure digitalis preparations, diuretics and theophylline -- if lung disease accompanies one of the above states -- are often used. Literature dealing with theophylline, digoxin and furosemide pharmacokinetics in edematous diseases was analyzed as well as theophylline or digoxin interactions with furosemide. The results obtained in these investigations are very dissimilar, even contradictory. In all the drugs investigated, it was found that serum drug concentration was reduced, that there were no changes in comparison with non-edematous diseases and that drug concentrations were elevated in edematous diseases. Many problems in this field remain unsolved requiring further investigations of digoxin, theophylline and furosemide pharmacokinetics in liver, heart and kidney diseases accompanied by edema. As these drugs are often administered in these states, and having in mind their narrow therapeutic range (digoxin, theophylline), intoxication or a drug concentration decrease below the possibility of inducing any therapeutic effect are possible.

Topics: Digoxin; Drug Interactions; Edema; Furosemide; Humans; Theophylline

Topics: Amino Acid Sequence; Animals; Atrial Natriuretic Factor; Blood Proteins; Cardenolides; Cattle; Digoxin; Dogs; Edema; Guinea Pigs; Humans; Hypertension; Hypothalamus; Kidney Failure, Chronic; Kidney Tubules; Muscle Proteins; Potassium; Rabbits; Saponins; Sodium; Sodium-Potassium-Exchanging ATPase

Topics: Aldosterone; Animals; Blood Volume; Cardiac Output; Diet, Sodium-Restricted; Digitalis Glycosides; Digoxin; Diuretics; Dog Diseases; Dogs; Edema; Extracellular Space; Heart Failure; Infusions, Parenteral; Kidney; Ouabain; Thirst

Topics: Ankle; Bicarbonates; Blood Glucose; Blood Pressure; Calcium; Chemical Phenomena; Chemistry; Chlorides; Clinical Trials as Topic; Creatinine; Digoxin; Diuresis; Diuretics; Edema; Furosemide; Humans; Potassium; Pulmonary Edema; Sodium Isotopes; Sulfonamides; Urea; Uric Acid; Urination

Topics: Aged; Arrhythmias, Cardiac; Atrial Fibrillation; Creatinine; Digitalis; Digoxin; Dyspnea; Edema; Female; Heart Failure; Humans; Male; Middle Aged; New York; Phytotherapy; Placebos; Plants, Medicinal; Plants, Toxic; Respiratory Insufficiency; Skilled Nursing Facilities; Time Factors

Topics: Administration, Oral; Adult; Aged; Clinical Trials as Topic; Digoxin; Edema; Female; Heart Diseases; Heart Rate; Humans; Injections, Intravenous; Intestinal Absorption; Male; Middle Aged

While in-utero treatment of sustained fetal supraventricular arrhythmia (SVA) is standard practice in the previable and preterm fetus, data are limited on best practice for late preterm (34 + 0 to 36 + 6 weeks), early term (37 + 0 to 38 + 6 weeks) and term (> 39 weeks) fetuses with SVA. We reviewed the delivery and postnatal outcomes of fetuses at ≥ 35 weeks of gestation undergoing treatment rather than immediate delivery.. This was a retrospective case series of fetuses presenting at ≥ 35 weeks of gestation with sustained SVA and treated transplacentally at six institutions between 2012 and 2022. Data were collected on gestational age at presentation and delivery, SVA diagnosis (short ventriculoatrial (VA) tachycardia, long VA tachycardia or atrial flutter), type of antiarrhythmic medication used, interval between treatment and conversion to sinus rhythm and postnatal SVA recurrence.. Overall, 37 fetuses presented at a median gestational age of 35.7 (range, 35.0-39.7) weeks with short VA tachycardia (n = 20), long VA tachycardia (n = 7) or atrial flutter (n = 10). Four (11%) fetuses were hydropic. In-utero treatment led to restoration of sinus rhythm in 35 (95%) fetuses at a median of 2 (range, 1-17) days; this included three of the four fetuses with hydrops. Antiarrhythmic medications included flecainide (n = 11), digoxin (n = 7), sotalol (n = 11) and dual therapy (n = 8). Neonates were liveborn at 36-41 weeks via spontaneous vaginal delivery (23/37 (62%)) or Cesarean delivery (14/37 (38%)). Cesarean delivery was indicated for fetal SVA in two fetuses, atrial ectopy or sinus bradycardia in three fetuses and obstetric reasons in nine fetuses that were in sinus rhythm at the time of delivery. Twenty-one (57%) cases were treated for recurrent SVA after birth.. In-utero treatment of the near term and term (≥ 35-week) SVA fetus is highly successful even in the presence of hydrops, with the majority of cases delivered vaginally closer to term, thereby avoiding unnecessary Cesarean section. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

Topics: Anti-Arrhythmia Agents; Atrial Flutter; Cesarean Section; Digoxin; Edema; Female; Fetal Diseases; Fetus; Humans; Hydrops Fetalis; Infant; Infant, Newborn; Pregnancy; Retrospective Studies; Tachycardia; Tachycardia, Supraventricular

In recent years, the drug repositioning strategy has gained considerable attention in the drug discovery process that involves establishing new therapeutic uses of already known drugs. In line with this, we have identified digoxin a cardiac glycoside, as a potent inhibitor of soluble epoxide hydrolase (sEH) enzyme employing in silico high throughput screening protocols and further confirmed using in vitro cell-free sEH inhibitory assay and in vivo preclinical studies in rodents for its repurposing in hyperalgesia, inflammation, and related disorders. Oral administration of digoxin at dose 0.2 mg/kg significantly reduced (p < .0001) the allodynia in mice induced by using hot plate (3.6 ± 1.9) and tail-flick test (7.58 ± 0.9). In addition, digoxin at a dose of 0.2 mg/kg showed marked reduction (94%, p < .0001) in acetic acid-induced abdominal contraction in rats. Further, digoxin also demonstrated antipyretic activity (37.04 ± 0.2, p < .0001) and showed notable reduction (0.60 ± 0.06) in carrageenan-induced paw edema in rats. Also, the histopathological evaluation revealed that digoxin treatment attenuated the edema, neutrophil infiltration, and alveolar septal thickening in lung tissue. These findings are novel and highlight the newer insights towards repurposing digoxin as a new lead in the treatment of hyperalgesia, inflammation, and related disorders.

Topics: Analgesics; Animals; Carrageenan; Digoxin; Drug Repositioning; Edema; Hyperalgesia; Inflammation; Mice; Pain; Rats

Topics: Asthenia; Cardiac Tamponade; Digoxin; Echocardiography; Edema; Erdheim-Chester Disease; Female; Humans; Kidney; Magnetic Resonance Imaging, Cine; Middle Aged; Prognosis

The optimal treatment for fetal supraventricular tachycardia (SVT) with 1:1 atrioventricular relationship is unclear.. We compared the effectiveness of transplacental treatment protocols used in 2 centers.. Pharmacologic treatment was used in 84 fetuses. Maternal oral flecainide was the primary therapy in center 1 (n = 34) and intravenous maternal digoxin in center 2 (n = 50). SVT mechanism was classified by mechanical ventriculoatrial (VA) time intervals as short VA or long VA. Treatment success was defined as conversion to sinus rhythm (SR), or rate control, defined as >15% rate reduction.. Short VA interval occurred in 67 fetuses (80%) and long VA in 17 (20%). Hydrops was present 28 of 84 (33%). For short VA SVT, conversion to SR was 29 of 42 (69%) for digoxin and 24 of 25 (96%) for flecainide (P = .01). For long VA SVT, conversion to SR and rate control was 4 of 8 (50%) and 0 of 8, respectively, for digoxin, and 6 of 9 (67%) and 2 of 9 (cumulative 89%) for flecainide (P = .13). In nonhydropic fetuses, digoxin was successful in 23 of 29 (79%) and flecainide in 26 of 27 (96%) (P = .10). In hydrops, digoxin was successful in 8 of 21 (38%), flecainide alone in 6 of 7 (86%, P = .07 vs digoxin), and flecainide ± amiodarone in 7 of 7 (100%) (P = .01). Intrauterine or neonatal death occurred in 9 of 21 hydropic fetuses treated with digoxin (43%), compared to 0 of 7 (P = .06) treated with flecainide.. Flecainide was more effective than digoxin, especially when hydrops was present. No adverse fetal outcomes were attributed to flecainide.

Topics: Administration, Intravenous; Administration, Oral; Adult; Anti-Arrhythmia Agents; Clinical Protocols; Digoxin; Echocardiography; Edema; Female; Fetal Diseases; Fetal Therapies; Flecainide; Humans; Pregnancy; Retrospective Studies; Tachycardia, Supraventricular; Ultrasonography, Prenatal; Young Adult

The current animal model generally accepted by the pharmaceutical industry and the FDA for assessment of muscle damage following intramuscular injection (IM) is the rabbit lesion volume model (RbLV). However, this model is resource intensive. The goal of this study was to find a resource sparing alternative to the rabbit lesion model for assessing injection site toleration in IM formulation screening.. Short term animal model alternatives to RbLV for evaluating IM formulations were examined. In addition to RbLV, myeloperoxidase (MPO), p-nitrophenyl N-acetyl-beta-glucosaminide (NA beta G) and/or plasma creatine phosphokinase (CK) activities were determined in rabbits (Rb) and rats (Rt) after injection of formulations (digoxin, azithromycin and danofloxacin). The edema from these formulations 24 hr after subcutaneous injection into the rat footpad (RFE) was also determined.. MPO and NA beta G were not considered very useful as biochemical predictors of muscle damage for these formulations. Histology generally correlated with RbLV values. Compared to saline, RbLV was marked for all formulations within 1-3 days of injection. After day 3, lesions quickly resolved, and no significant differences were found. For these formulations, all CK animal models and RFE were generally predictive of RbLV. A formulation with RtCK > 1000 U/L or RbCK > 3000 U/L, was predicted to be poorly, tolerated.. Due to ease, number of animals, time and intrinsic mechanism, we concluded that for most formulations, 2 and 4 hr RtCK data alone should be reasonably predictive of muscle damage.

Topics: Acetylglucosaminidase; Animals; Chemistry, Pharmaceutical; Creatine Kinase; Digoxin; Disease Models, Animal; Drug Evaluation, Preclinical; Edema; Evaluation Studies as Topic; Hemorrhage; Injections, Intramuscular; Male; Muscles; Peroxidase; Rabbits; Rats; Rats, Sprague-Dawley

Topics: Animals; Anti-Infective Agents; Azithromycin; Cells, Cultured; Chemistry, Pharmaceutical; Creatine Kinase; Digoxin; Disease Models, Animal; Drug Evaluation, Preclinical; Edema; Evaluation Studies as Topic; Fluoroquinolones; Injections, Intramuscular; Muscle, Skeletal; Predictive Value of Tests; Quinolones; Rabbits; Rats

Fetal supraventricular tachycardia (SVT) can be successfully treated transplacentally, but in cases where fetal hydrops develops there is considerable morbidity and mortality. The present study was carried out to establish whether the introduction of flecainide altered obstetric management and fetal outcome. A retrospective analysis took place of 51 singleton pregnancies which were referred to the division of prenatal diagnosis because of fetal tachycardia between 1982 and 1993. SVT was documented in 50 out of 51 fetuses, one of which displayed a combination of extensive rhabdomyomas and severe hydrops and died shortly after referral. In the other fetus ventricular tachycardia was diagnosed. Of the remaining 49 fetuses, 14 did not receive any prenatal treatment, but nine needed postnatal treatment. Transplacental treatment of SVT took place in 35 fetuses, of which 22 presented without hydrops and 13 with hydrops. These subsets differed significantly with respect to restoration of normal sinus rhythm (73% vs. 30%; p < 0.001) and mortality (0% vs. 46%; p < 0.001). Digoxin was effective in restoring sinus rhythm in 55 per cent of the non-hydropic fetuses but in only eight per cent of the hydropic fetuses. Flecainide was effective in restoring sinus rhythm in all non-hydropic fetuses where digoxin treatment failed, and in 43 per cent of hydropic fetuses. Administration of flecainide resulted in a significantly reduced mortality (p < 0.001) compared with digoxin treatment. No adverse effects were seen. Postnatal anti-arrhythmic treatment was necessary in 23 infants. Treatment could be withdrawn within one year in all cases but one.

Topics: Anti-Arrhythmia Agents; Digoxin; Edema; Female; Fetal Diseases; Flecainide; Humans; Pregnancy; Retrospective Studies; Survival Rate; Tachycardia, Supraventricular; Treatment Outcome

A study was conducted on the pharmacological actions of the toad venom-containing drug "Kyushin" (KY-2 and KY-R) on urinary volume and electrolytes excretion, regional blood flow, renal artery blood flow and carrageenin-induced hind-paw edema. In rabbits, KY-2 and KY-R significantly increased urinary volume after intravenous administration of 8 mg/kg. In guinea pigs, KY-2 and KY-R produced a significant increase in urinary volume after intraduodenal administration (i.d.) of 80 mg/kg. In guinea pigs treated with propranolol, KY-2 at 20 and 40 mg/kg p.o. and KY-R at 40 mg/kg p.o. increased urinary volume. At 40 mg/kg i.d. both KY-2 and KY-R produced an increase in regional blood flow, as determined by the hydrogen gas clearance method, of the brain areas including the amygdaloid nucleus, but did not affect regional blood flow in liver, kidney and skeletal muscle, or renal artery blood flow. In rats, carrageenin-induced hind-paw edema was inhibited by KY-2 or KY-R at 600 mg/kg p.o.

Topics: Animals; Bufanolides; Carrageenan; Digoxin; Drug Evaluation, Preclinical; Duodenum; Edema; Electrolytes; Guinea Pigs; Hemodynamics; Injections, Intravenous; Intubation, Gastrointestinal; Liver; Male; Materia Medica; Muscles; Propranolol; Rabbits; Rats; Rats, Wistar; Renal Artery; Renal Circulation; Urine

Intrauterine resolution of a case of nonimmune hydrops fetalis associated with cytomegalovirus infection occurred during conservative antenatal management. Although the etiology for a case of nonimmune hydrops diagnosed antenatally is often obscure, a systematic investigation provided an antenatal diagnosis of cytomegalovirus infection, permitting expectant management and eventual vaginal delivery at term.

Topics: Adult; Agenesis of Corpus Callosum; Cytomegalovirus Infections; Digoxin; Edema; Female; Fetal Diseases; Fetal Monitoring; Humans; Infant, Newborn; Male; Pregnancy; Prenatal Diagnosis; Ultrasonography

During 1980-7, 23 pregnancies of 22-38 weeks' duration were investigated for fetal tachycardia. Twelve were cases of supraventricular tachycardia, eight of atrial flutter, and three cases in which the rhythm varied between supraventricular tachycardia and atrial flutter. In 11 cases the fetus had developed non-immune fetal hydrops before referral; 12 cases were non-hydropic at referral but one of this group of fetuses became hydropic during treatment. No relation was found between the rate or type of arrhythmia and the presence or absence of intrauterine heart failure. One non-hydropic infant was delivered electively prematurely. Maternal antiarrhythmic treatment was instituted in the remaining 22 cases. Conversion of the arrhythmia was achieved with digoxin alone in five cases and with a combination of digoxin and verapamil in nine. Control of the arrhythmia was achieved in seven of the 10 non-hydropic fetuses, and all were delivered at term with no deaths. Of the 12 hydropic fetuses, control was achieved in seven. Only three of the hydropic fetuses were delivered close to term. There were two deaths, both in the hydropic group. Of the whole group, five neonates suffered severe complications of prematurity. In this series the main benefit of treatment appeared to be in prolonging gestation of those hydropic fetuses in which conversion was achieved.

Topics: Delivery, Obstetric; Digoxin; Drug Therapy, Combination; Edema; Female; Fetal Diseases; Heart Failure; Heart Rate, Fetal; Humans; Infant, Newborn; Maternal-Fetal Exchange; Pregnancy; Tachycardia; Verapamil

A case of severe nonimmune hydrops fetalis caused by supraventricular tachycardia is presented. Maternal treatment with digoxin and the subsequent addition of verapamil and propranolol failed to be effective. Simultaneous measurement of maternal serum and cord blood digoxin levels showed insufficient transplacental digoxin transfer. Other modalities of treatment are discussed.

Topics: Adult; Digoxin; Edema; Female; Fetal Diseases; Humans; Maternal-Fetal Exchange; Pregnancy; Propranolol; Tachycardia, Supraventricular; Verapamil

Successful treatment of intrauterine fetal tachyarrhythmia was reported in several cases recently. It was also pointed out that placental transfer of digoxin is unsatisfactory under certain conditions. However, it has not been clearly shown in which cases fetal digoxin level does not reach the maternal level. We present a case of nonimmune hydrops fetalis due to congenital atrial flutter in which digoxin concentration in the sera of the mother and the neonate showed significant dissociation, and discuss perinatological matters about the digoxin treatment and the factor that obstructs the transplacental passage of digoxin. Conclusively, we recommend that maternal digoxin concentration should be raised to near toxic level if the resolution of fetal and placental hydrops is not attained in the initial digoxin loading.

Topics: Adult; Atrial Flutter; Digoxin; Echocardiography; Edema; Female; Fetal Diseases; Heart Failure; Humans; Infant, Newborn; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications; Recurrence

Topics: Digoxin; Edema; Female; Fetal Diseases; Humans; Infant, Newborn; Maternal-Fetal Exchange; Pregnancy; Prenatal Diagnosis; Respiration, Artificial; Ultrasonography

Topics: Adult; Digoxin; Edema; Female; Fetal Diseases; Humans; Male; Maternal-Fetal Exchange; Pregnancy; Tachycardia, Supraventricular

The rational therapy of cardiovascular disease in horses requires a thorough knowledge of the pharmacology and pharmacokinetics of several specific drugs (digitalis, digoxin). Calcium solutions, dopamine, and dobutamine are frequently used to treat congestive heart failure in horses. Quinidine, procainamide, lidocaine, and propranolol are used to treat a variety of supraventricular and ventricular arrhythmias. Furosemide, a highly potent loop diuretic, is used to eliminate edema and promote diuresis. A thorough understanding of the applied pharmacology, dosage recommendations, toxicity, and practical considerations must be attained before these drugs can be used effectively.

Topics: Administration, Oral; Animals; Arrhythmias, Cardiac; Cardiovascular Agents; Digoxin; Diuretics; Dobutamine; Dopamine; Drug Administration Schedule; Edema; Heart Diseases; Heart Failure; Heart Rate; Hemodynamics; Horse Diseases; Horses; Injections, Intravenous; Lidocaine; Procainamide; Propranolol; Quinidine

Two cases of supraventricular tachycardia responsible for hydrops fetalis emphasize the interest of an antenatal echocardiography. The systematic use of this technique will increase the frequency of diagnosis of this etiology in other cases where the prognosis is less favorable. The in utero treatment of this rhythmic disorder consists in administering Digoxin to the mother and the newborn child must receive excellent care from the moment of the birth.

Topics: Digoxin; Echocardiography; Edema; Female; Fetal Diseases; Humans; Infant, Newborn; Pregnancy; Prenatal Diagnosis; Tachycardia, Paroxysmal; Ultrasonography

Ultrasound is becoming more and more important in the routine care of antenatal patients. It makes it possible to diagnose a certain number of fetal abnormalities and in particular fetoplacental oedema whether it is caused by immunological or other factors. If oedema is associated with fetal cardiac arrhythmic conditions it can in certain cases be treated and cured in utero. This work analyses 11 cases of fetal oedema diagnosed by routine ultrasound in the years between 1977 and 1984.

Topics: Adult; Digoxin; Edema; Female; Fetal Diseases; Humans; Pregnancy; Tachycardia; Ultrasonography; Verapamil

Intrauterine fetal supraventricular tachycardia is a rare condition often associated with the syndrome of nonimmune hydrops fetalis. When the fetus is preterm it is vital to treat the arrhythmia with maternally administered drugs and different regimens have been reported in the literature. We report 1 case of this arrhythmia successfully treated in utero with maternally administered digoxin resulting in complete reversal of the hydrops fetalis and the birth of a healthy baby. A review of the relevant literature is brought forth.

Topics: Digoxin; Edema; Female; Fetal Diseases; Humans; Pregnancy; Prenatal Diagnosis; Tachycardia

In a fetus with supraventricular tachycardia (SVT) and cardiac failure, normal sinus rhythm (NSR) was restored with maternal digoxin therapy at 26 weeks' gestation. The diagnosis of cardiac failure was based on ultrasound evidence of ascites and scalp edema. Cardiac failure was attributed to the persistent SVT. The infant remained in NSR and was delivered at 36 weeks' gestation because of persistent ascites. Intracardiac anatomy was normal. This case confirms the usefulness of prenatal ultrasound examinations in the diagnosis of fetal SVT and cardiac failure and illustrates the effectiveness and safety of transplacental digoxin therapy in the management of fetal SVT.

Topics: Adult; Ascites; Cesarean Section; Digoxin; Edema; Female; Fetal Diseases; Fetal Heart; Humans; Infant, Newborn; Male; Maternal-Fetal Exchange; Polyhydramnios; Pregnancy; Tachycardia

Perinatal outcome of fetal supraventricular tachycardia. Report of 5 cases and review of the literature. Fetal supraventricular tachycardia (fsVT) is a rare cardiac arrhythmia and is associated with a mortality of 12%. The last decade fsVT has been detected more frequently probably on account of routine fetal monitoring. The outcome of 108 previously reported cases has been reviewed and 5 cases are added. Congestive heart-failure due to fsVT was seen quite frequently. Delivery by caesarean section was performed in 33% of fsVT-cases. Treatment of the condition before and after birth is discussed; digitalis is the drug of choice. A guide-line for delivery is suggested. fsVT should be listed among the possible causes of hydrops foetalis. On request a complete list of references concerning fetal supraventricular tachycardia is available from the authors.

Topics: Digoxin; Edema; Female; Fetal Diseases; Furosemide; Humans; Infant, Newborn; Male; Pregnancy; Tachycardia

Topics: Adult; Cesarean Section; Digoxin; Edema; Female; Fetal Diseases; Humans; Infant, Newborn; Male; Pregnancy; Tachycardia, Paroxysmal; Verapamil

Topics: Cesarean Section; Digoxin; Echocardiography; Edema; Female; Fetal Diseases; Fetal Heart; Humans; Infant Care; Infant, Newborn; Pregnancy; Prenatal Diagnosis; Propranolol; Ultrasonography

Topics: Cesarean Section; Digoxin; Edema; Female; Fetal Diseases; Fetal Heart; Humans; Infant; Infant, Newborn; Male; Pregnancy; Sex Factors; Tachycardia

A critically ill infant with paroxysmal supraventricular tachycardia and hydrops fetalis responded well to aggressive management. Care must be taken to avoid digitalis toxicity. Procaine amide or quinidine are effective alternate therapies.

Topics: Digoxin; Edema; Electrocardiography; Female; Fetal Diseases; Furosemide; Heart Ventricles; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Positive-Pressure Respiration; Pregnancy; Procainamide; Tachycardia, Paroxysmal; Water

Topics: Aged; Asthma; Bronchitis; Carbon Dioxide; Cardiac Catheterization; Conjunctiva; Diet, Sodium-Restricted; Digoxin; Edema; Eye Diseases; Female; Furosemide; Heart Failure; Humans; Hyperemia; Male; Middle Aged; Oxygen; Oxygen Inhalation Therapy; Potassium Chloride; Pulmonary Emphysema; Pulmonary Fibrosis; Pulmonary Heart Disease; Respiratory Insufficiency; Veins

Topics: Digoxin; Diuretics; Edema; Female; Humans; Malignant Carcinoid Syndrome; Middle Aged; Phonocardiography; Radiography

Topics: Digoxin; Edema; Heart Failure; Humans; Hypocalcemia; Hyponatremia; Infant, Newborn; Infant, Newborn, Diseases; Magnesium

Topics: Blood Transfusion, Intrauterine; Digoxin; Edema; Erythroblastosis, Fetal; Female; Gestational Age; Humans; Hydrochlorothiazide; Methods; Pregnancy

Topics: Atrial Flutter; Birth Weight; Body Weight; Digoxin; Edema; Electrocardiography; Female; Fetal Diseases; Fetal Heart; Furosemide; Heart Failure; Heart Rate; Humans; Infant, Newborn; Infant, Newborn, Diseases; Male; Pregnancy

Topics: Anti-Bacterial Agents; Antilymphocyte Serum; Arrhythmias, Cardiac; Australia; Azathioprine; Betamethasone; Blood Pressure; Blood Sedimentation; Digoxin; Edema; Electrocardiography; Furosemide; Glycosuria; Heart Auscultation; Heart Transplantation; Hemorrhage; Humans; Hydrocortisone; Hydroxybutyrate Dehydrogenase; Immunosuppressive Agents; Infections; Infusions, Parenteral; Injections, Intramuscular; Injections, Intravenous; Intensive Care Units; Isoproterenol; Male; Middle Aged; Postoperative Complications; Respiration; Transplantation Immunology; Transplantation, Homologous; Veins

Topics: Age Factors; Arteriosclerosis; Atrial Fibrillation; Body Weight; Digoxin; Edema; Female; Heart Failure; Heart Rate; Humans; Hypertension; Lung Diseases; Male; Middle Aged; Organ Size; Spirometry; Syphilis, Cardiovascular

Topics: Amniotic Fluid; Antigens; Blood Transfusion, Intrauterine; Cesarean Section; Digoxin; Edema; Erythroblastosis, Fetal; Female; Humans; Hydrochlorothiazide; Immunization; Infant, Newborn; Infant, Premature; Oxytocin; Plasmapheresis; Pregnancy; Rh-Hr Blood-Group System

Topics: Aged; Body Weight; Digoxin; Diuretics; Drug Synergism; Edema; Female; Furosemide; Glycosuria; Humans; Hypertension; Male; Middle Aged; Natriuresis; Potassium; Spironolactone; Strophanthins; Tolbutamide

Topics: Cardiac Catheterization; Cardiomyopathies; Desoxycorticosterone; Diagnosis; Digoxin; Drug Therapy; Edema; Guanethidine; Heart Diseases; Heart Failure; Humans

Topics: Adrenalectomy; Ascites; Blood Transfusion; Chlorothiazide; Digoxin; Diuretics; Edema; Ethacrynic Acid; Geriatrics; Heart Failure; Humans; Injections, Intravenous; Liver Cirrhosis; Pulmonary Edema

Topics: Diet, Sodium-Restricted; Digoxin; Edema; Geriatrics; Heart Failure; Humans; Medicine, Ayurvedic; Physical Exertion; Vitamin A; Vitamins